Combination Treatment With Bosentan and Sildenafil to Patients With Eisenmengers Syndrome

Overview

The purpose of this study is to investigate if combination treatment with Bosentan and Sildenafil to patients with Eisenmenger syndrome is beneficial.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Double
  • Study Primary Completion Date: January 2008

Detailed Description

Eisenmengers syndrome is condition with severe pulmonary arterial hypertension due to a shunting of blood from the left side of the heart to the right side of the heart. When the pressure in the pulmonary arteries levels the systemic blood pressure, blood begins to shunt from the right side of the heart to the left side of the heart leading to a condition with cyanosis, impaired physical capacity and increased mortality (Eisenmengers syndrome). Several clinical trials have shown that there is a beneficial effect of treating patients with primary pulmonary arterial hypertension with Bosentan or Sildenafil and that a combination of these may have an additive or even synergistic effect. No clinical trials with Sildenafil and Bosentan has been conducted for patients with Eisenmengers syndrome. Observational studies and case stories indicate however that the effect of Bosentan or Sildenafil in patients with Eisenmengers syndrome may be as promising in these patients as in patients with primary pulmonary arterial hypertension. We would like to examine the effect of treating patients with Eisenmengers Syndrome with a combination of Bosentan and Sildenafil. The primary end point is change in physical performance measured with six minutes walking test. Secondary end points is change in saturation, NYHA class, cardiac output (cardiac catheterization and innocor measurement), pulmonary vascular resistance (cardiac catheterization) shunt ratio (MRI), strain of right ventricle (BNP and echocardiography), quality of life and serum erythropoitin. The trial is designed as a randomized, single centre, placebo controlled, double blind cross over study. Twenty patients with Eisenmengers syndrome is included. All patients will be treated in three months with Bosentan. There after patients will be randomized to receive either Sildenafil (50 mg tid) or placebo as add on therapy for three month. Hereafter a cross over will be made and patients in combination treatment will receive only their native treatment and vice versa. Examinations for primary and secondary endpoints will be made at baseline, before cross over and at the end of the study. All up titrating of medication will be performed during admittance. Patients will during the study period be close monitored with registration of adverse advents, physical examination and blood tests.

Interventions

  • Drug: Bosentan and Sildenafil

Clinical Trial Outcome Measures

Primary Measures

  • 6 minutes walking distance

Secondary Measures

  • Pulmonary blood flow
  • Systemic blood flow
  • Pulmonary resistance
  • Shunt ratio
  • Erythropoitin
  • BNP
  • Saturation in rest
  • Saturation in activity
  • Quality of life
  • Right ventricle systolic and diastolic function
  • Working capacity
  • Oxygen consumption at rest
  • Oxygen consumption during maximal work

Participating in This Clinical Trial

Inclusion Criteria

  • Eisenmenger syndrome – Negative pregnancy test Exclusion Criteria:

  • Elevated liver enzymes to more than 3´times normal value – Hypotension (SBP < 90 mmhg). – Mandatory treatment with nitrates – Myocardial infarction within 3 months – Stroke within 3 months – Known allergy to Bosentan or Sildenafil – inherited degenerative diseases in retina – Breast feeding – Suspicion of risc of noncompliance.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rigshospitalet, Denmark
  • Provider of Information About this Clinical Study
    • Kasper Iversen, Rigshospitaler
  • Overall Official(s)
    • Lars Soendergaard, MD, Principal Investigator, Rigshospitalet, Denmark

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.